We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+102.44%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$85.3M
Cap. Flow
+$31.5M
Cap. Flow %
16.85%
Top 10 Hldgs %
57.79%
Holding
64
New
29
Increased
5
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$13.7M
2
SION
Sionna Therapeutics
SION
+$6.85M
3
DVAX
Dynavax Technologies
DVAX
+$5.79M
4
DFTX
Definium Therapeutics
DFTX
+$5.26M
5
AXSM icon
Axsome Therapeutics
AXSM
+$5.23M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$7.99M
2
ETNB
89bio
ETNB
+$5.65M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$5.39M
4
BBIO icon
BridgeBio Pharma
BBIO
+$4.6M
5
SMMT icon
Summit Therapeutics
SMMT
+$4.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
1
DELISTED
Cidara Therapeutics
CDTX
$18.8M 10.06%
85,098
+16,635
+24% +$2.69M
TERN
2
DELISTED
Terns Pharmaceuticals
TERN
$17.9M 9.6%
443,777
-345,869
-44% -$7.99M
URGN icon
3
UroGen Pharma
URGN
$1.96B
$16.8M 9.01%
718,354
+630,442
+717% +$13.7M
COGT icon
4
Cogent Biosciences
COGT
$6.68B
$13M 6.96%
366,238
+4,830
+1% +$136K
DVAX
5
DELISTED
Dynavax Technologies
DVAX
$8.08M 4.33%
+525,592
New +$5.79M
SION
6
Sionna Therapeutics
SION
$2.23B
$7.43M 3.98%
+180,593
New +$6.85M
IMVT icon
7
Immunovant
IMVT
$8.27B
$7.34M 3.93%
288,677
-52,671
-15% -$1.17M
AXSM icon
8
Axsome Therapeutics
AXSM
$11.8B
$6.84M 3.66%
+37,433
New +$5.23M
SVRA icon
9
Savara
SVRA
$1.13B
$6M 3.21%
995,353
-313,883
-24% -$1.54M
DFTX
10
Definium Therapeutics
DFTX
$5.88B
$5.69M 3.05%
+425,202
New +$5.26M
TSHA icon
11
Taysha Gene Therapies
TSHA
$1.71B
$5.39M 2.89%
+980,768
New +$4.76M
OCUL icon
12
Ocular Therapeutix
OCUL
$1.96B
$5.08M 2.72%
+418,080
New +$5.08M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$5.03M 2.69%
+352,896
New +$3.47M
CABA icon
14
Cabaletta Bio
CABA
$461M
$4.94M 2.64%
2,253,550
+709,025
+46% +$1.76M
UTHR icon
15
United Therapeutics
UTHR
$22.7B
$4.61M 2.47%
+9,451
New +$4.4M
RVMD icon
16
Revolution Medicines
RVMD
$39.6B
$4.37M 2.34%
+54,879
New +$3.6M
BLTE
17
Belite Bio
BLTE
$6.02B
$3.95M 2.12%
+24,703
New +$2.93M
DRUG
18
Bright Minds Biosciences
DRUG
$747M
$3.69M 1.98%
47,278
-6,672
-12% -$446K
ZLAB icon
19
Zai Lab
ZLAB
$2.28B
$3.47M 1.86%
196,853
-3,775
-2% -$88.4K
ZBIO
20
Zenas BioPharma
ZBIO
$1.86B
$3.03M 1.62%
83,353
-13,312
-14% -$438K
QNCX icon
21
Quince Therapeutics
QNCX
$18.5M
$2.88M 1.54%
+4,294
New +$2.16M
AVTX icon
22
Avalo Therapeutics
AVTX
$1.02B
$2.78M 1.49%
153,313
-34,767
-18% -$587K
CAPR icon
23
Capricor Therapeutics
CAPR
$1.13B
$2.78M 1.49%
+96,334
New +$1.26M
PVLA
24
Palvella Therapeutics
PVLA
$2.26B
$2.67M 1.43%
+25,469
New +$2.17M
CLDX icon
25
Celldex Therapeutics
CLDX
$2.77B
$2.4M 1.28%
+88,308
New +$2.33M
1
2 3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Superstring Capital Management held 64 positions worth $187M, up 84% from $102M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management deployed $31.5M of net new capital in Q4 2025, opening 29 new positions and adding to 5 existing holdings. Its largest new stake was Sionna Therapeutics: 180,593 shares worth $7.43M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $7.99M trimmed.

  • Superstring Capital Management's largest Q4 2025 buy was Sionna Therapeutics: 180,593 shares worth $7.43M.
  • Superstring Capital Management added most to UroGen Pharma in Q4 2025, an estimated $13.7M increase.
  • Superstring Capital Management's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $7.99M.
  • Superstring Capital Management fully exited 89bio in Q4 2025, selling an estimated $5.65M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $187M portfolio in Q4 2025.
  • Superstring Capital Management opened 29 new positions and closed 19 in Q4 2025.
  • Superstring Capital Management's portfolio value rose 84% quarter-over-quarter to $187M.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.